A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis. Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period. During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.

NCT Number	NCT07326813
Lead Sponsor	InventisBio Co., Ltd
Conditions	Plaque Psoriasis
Enrollment	477 participants
Start Date	2026-01-12
Primary Completion	2027-07-12 (estimated)
Study Completion	2027-12-03 (estimated)
Updated on ClinicalTrials.gov	2026-04-29